Document text
Principal Investigator: TERRY L. SHEPPARD
Organization: KEYSTONE SYMPOSIA
Fiscal Year: 2024
Award: $6,000
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT
Support is requested for a Keystone Symposia conference entitled Fungal Pathogens: Emerging Threats and
Future Challenges, organized by Drs. Michail Lionakis, Sarah Gaffen and Mari Shinohara. The conference will
be held in Banff, Alberta, Canada from February 18-21, 2024.
Human pathogenic fungi have emerged as significant causes of morbidity and mortality in patients with acquired
immunodeficiency conditions such as HIV/AIDS, as well as in receipt of myeloablative chemotherapy and
targeted immunosuppressive therapies for autoimmune disorders, neoplastic diseases, and in hematopoietic
stem cell and solid organ transplantation. Moreover, in recent years, emerging multidrug resistant Candida auris
has been responsible for life-threatening outbreaks in healthcare facilities and raises serious concerns to global
public health. Furthermore, a recent surge in the discovery and characterization of novel monogenic inborn errors
of immunity that have been predisposed to mucocutaneous and/or invasive tissue-specific fungal disease, along
with the development of clinically relevant animal models of mucocutaneous and invasive fungal infections, have
collectively enhanced our understanding of cell type-, tissue-, and fungus-specific recognition, effector pathways,
and adaptive immune responses. These advances, along with our improved molecular understanding of fungal
virulence traits, highlight the promise for rapid development of targeted treatment strategies against fungal
pathogens. Therefore, this Keystone Symposia conference will bring together, for the first time, scientists who
study fungal virulence and fungal immunology, thus helping to synthesize current understanding of the cellular
and molecular determinants of fungal pathogenesis and mammalian antifungal immunity. By encouraging cross-
disciplinary exchange, this conference will advance key priorities of informing precision risk stratification, and
defining prophylactic, therapeutic and vaccination strategies to combat life-threatening fungal infections in
vulnerable patient populations.
Terms: <AIDS/HIV><Alberta><Alberta province><Animal Model><Animal Models and Related Studies><Anti-Rejection Therapy><Autoimmune Diseases><Biology><Blood Precursor Cell><Body Tissues><C. Auris resistance><Canada><Clinical Management><Collaborations><Communities><Development><Disease><Disease Outbreaks><Disorder><Educational workshop><Electronic Medical Records and Genomics Network><Fungus Diseases><Future><Goals><Grafting Procedure><HIV/AIDS><Health Facilities><Health care facility><Healthcare Facility><Hematopoietic Progenitor Cells><Hematopoietic stem cells><Human><Immune system><Immunity><Immunologist><Immunology><Immunosuppressive Therapy><International><Investigation><Investigators><Knowledge><Learning><Life><Methodology><Modern Man><Molecular><Morbidity><Morbidity - disease rate><Multi-Drug Resistance><Multidrug Resistance><Multiple Drug Resistance><Multiple Drug Resistant><Mycology><Mycoses><Myeloablative Chemotherapy><Organ Transplantation><Organ Transplants><Outbreaks><Outcome><Participant><Pathogenesis><Pathway interactions><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Predisposition><Primary Immunodeficiency><Public Health><Regulation><Research><Research Personnel><Researchers><Resistance to Multi-drug><Resistance to Multidrug><Resistance to Multiple Drug><Resistant to Multiple Drug><Resistant to multi-drug><Resistant to multidrug><Running><Scientist><Site><Solid><Susceptibility><Symbiosis><Technology><The science of Mycology><Therapeutic><Therapeutic Fungicides><Therapeutic immunosuppression><Time><Tissues><Translations><Virulence><Work><Workshop><acquired immunodeficiency><adaptive immune response><anti-fungal><anti-fungal agents><anti-fungal drug><artificial immunosuppression><autoimmune condition><autoimmune disorder><autoimmunity disease><blood cell progenitor><blood progenitor><blood stem cell><blood-forming stem cell><care facilities><career development><cell type><clinical development><clinical implementation><clinical practice><clinical prognosis><clinical relevance><clinically relevant><combat><commensalism><conference><congenital immune deficiency><congenital immunodeficiency><convention><developmental><eMERGE Consortium><eMERGE Network><frontier><fungal infection><fungal pathogen><fungi pathogen><fungus><fungus infection><genetic immune defect><genetic immune deficiency><genetic immunodeficiency><hematopoietic progenitor><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><immunization strategy><immunosuppression therapy><improved><inborn errors in immunity><inborn errors of immunity><inborn immunodeficiency><inherited immune defect><inherited immune deficiency><inherited immunodeficiency><interdisciplinary approach><interest><meeting><meetings><member><model of animal><mortality><multi-drug resistant><multidisciplinary><multidisciplinary approach><multidrug resistant><neoplastic><novel><organ allograft><organ graft><organ xenograft><pathogenic fungus><pathway><patient oriented outcomes><patient population><posters><primary immune defect><primary immune deficiency><prophylactic><resistance development in C. Auris><resistance in Candida auris><resistant Candida auris><risk stratification><stratify risk><summit><symposia><symposium><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><trait><translation><treatment strategy><vaccination strategy>